A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder

Therapeutic Drug Monitoring

Volumn 35, Issue 2, 2013, Pages 194-202

  Prossin, Alan R ^a   Zalcman, Steven S ^b,c   Evans, Simon J ^a   McInnis, McInnis G ^a   Ellingrod, Vicki L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

atypical antipsychotic; bipolar disorder; cytokines; mediation; metabolic syndrome; psychoneuroimmunology; tumor necrosis factor

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; VOLUNTEER; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PILOT PROJECTS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84875130463     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31827e18d2     Document Type: Article

References (40)

1. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005; 7: 424-430.
2. Fiedorowicz JG, Palagummi NM, Forman-Hoffman VL, et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder. Ann Clin Psychiatry. 2008; 20: 131-137.
3. Vuksan-Cusa B, Jakovljevic M, Sagud M, et al. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA. Psychiatry Res. 2011; 189(1): 21-25.
4. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008; 101: 273-286.
5. ATP-III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001; 285: 2486-2497.
6. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004; 24: e13-e18.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-359.
8. Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008; 10: 788-797.
9. Guo JJ, Keck PE, Li H, et al. Treatment costs related to bipolar disorder and comorbid conditions among Medicaid patients with bipolar disorder. Psychiatr Serv. 2007; 58: 1073-1078.
10. Kemp DE, Calabrese JR, Tran QV, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010; 71: 1138-1144.
11. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007; 98: 247-252.
12. Cardenas J, Frye MA, Marusak SL, et al. Modal subcomponents of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008; 106: 91-97.
13. Fagiolini A, Chengappa KN, Soreca I, et al. Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden. CNS Drugs. 2008; 22: 655-669.
14. Garcia-Portilla MP, Saiz PA, Benabarre A, et al. The prevalence of metabolic syndrome in patients with bipolar disorder. J Affect Disord. 2008; 106: 197-201.
15. Taylor V, MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry. 2006; 67: 1034-1041.
16. van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008; 10: 342-348.
17. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol. 2005; 46: 1978-1985.
18. Lee SC, Pu YB, Thomas GN, et al. Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism. 2000; 49: 1021-1024.
19. Kern PA. Potential role of TNFalpha and lipoprotein lipase as candidate genes for obesity. J Nutr. 1997; 127: 1917S-1922S.
20. Saghizadeh M, Ong JM, Garvey WT, et al. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest. 1996; 97: 1111-1116.
21. Stephens JM, Carter BZ, Pekala PH, et al. Tumor necrosis factor alphainduced glucose transporter (GLUT-1) mRNA stabilization in 3T3-L1 preadipocytes. Regulation by the adenosine-uridine binding factor. J Biol Chem. 1992; 267: 8336-8341.
22. Stephens JM, Pekala PH Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulation is coordinate and independent of protein synthesis. J Biol Chem. 1992; 267: 13580-13584.
23. Brietzke E, Stertz L, Fernandes BS, et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord. 2009; 116: 214-217.
24. Elisa B, Beny L. Induction of manic switch by the tumour necrosis factor-alpha antagonist infliximab. Psychiatry Clin Neurosci. 2010; 64: 442-443.
25. Kim YK, Jung HG, Myint AM, et al. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord. 2007; 104: 91-95.
26. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 23(suppl 62): 45-66.
27. Beck AT, Steer RA, Beck JS, et al. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat Behav. 1993; 23: 139-145.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
29. Orrell A, Doherty P, Miles J, et al. Development and validation of a very brief questionnaire measure of physical activity in adults with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2007; 14: 615-623.
30. Berkley KJ, Zalcman SS, Simon VR. Sex and gender differences in pain and inflammation: a rapidly maturing field. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R241-R244.
31. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223.
32. Andreasen NC, Pressler M, Nopoulos P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010; 67: 255-262.
33. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64: 663-667.
34. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods. 2004; 36: 717-731.
35. Hayes AF, Preacher KJ. Quantifying and testing indirect effects in simple mediation models when the constituent paths are nonlinear. Multivariate Behavioral Research. 2010; 45: 627-660.
36. Hayes AF. Beyond Baron and Kenny: statistical mediation analysis in the new millennium. Commun Monogr. 2009; 76: 13.
37. Mathieu JE, Taylor SR. Clarifying conditions and decision points for mediational type inferences in organizational behavior. J Personality Soc Psychol. 2006; 89: 12.
38. Hayes AF, Preacher KJ, Myers TA. Mediation and the estimation of indirect effects in political communication research. In: Bucy EP, Holbert RL, eds. Sourcebook for Political Communication Research: Methods, Measures, and Analytical Techniques. London, United Kingdom: Routledge; 2011: 434-465.
39. Kim YK, Myint AM, Lee BH, et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Res. 2004; 129: 267-272.
40. Kunz M, Cereser KM, Goi PD, et al. Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro-and anti-inflammatory balance. Rev Bras Psiquiatr. 2011; 33: 268-274.